Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
3
×
clinical trials
fda
life sciences
national blog main
san diego blog main
san diego top stories
3
×
boston blog main
boston top stories
national top stories
new york blog main
new york top stories
san francisco blog main
san francisco top stories
akcea therapeutics
alnylam pharmaceuticals
arena pharmaceuticals
barry greene
bial
boston
boston university
boulder/denver blog main
boulder/denver top stories
cancer
cardiovascular disease
colorectal cancer
dan ollendorf
detroit blog main
detroit top stories
drug development
drugs
eisai
europe blog main
europe top stories
hereditary transthyretin amyloidosis
indiana blog main
indiana top stories
inotersen
john berk
lorcaserin
What
fda
3
×
patients
3
×
medicine
time
add
ago
alnylam
approve
awaits
biological
called
cancer
carbidopa
combination
control
crossed
daily
decades
decision
discovered
disease
drug
eisai
experience
fingers
flags
friday
gets
higher
historic
incidence
levodopa
lorcaserin
loss
market
marketing
medication
neurocrine
nod
parkinson’s
Language
unset
Current search:
biotech
×
patients
×
" san diego top stories "
×
fda
×
@xconomy.com
4 years ago
Neurocrine Gets FDA Nod for Once-Daily “Add-On” Parkinson’s Pill
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision